![BerGenBio ASA logo](/logos/BGBIO.OL.webp)
BerGenBio ASA
OSE:BGBIO.OL
Overview | Financials
Company Name | BerGenBio ASA |
Symbol | BGBIO.OL |
Currency | NOK |
Price | 0.152 |
Market Cap | 398,320,548 |
Dividend Yield | 0% |
52-week-range | 0.075 - 9.8 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Martin Olin |
Website | https://www.bergenbio.com |
An error occurred while fetching data.
About BerGenBio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD